Abstract
The level of plasma cholesterol is related to long-term prognosis in patients with coronary heart disease. Lowering of plasma lipid levels and normalization of lipoprotein profiles, therefore, is an integral part of secondary prevention. Evidence for its efficacy comes from epidemiological and clinical intervention studies and from well controlled clinical trials aimed at demonstrating regression of atherosclerosis.
Measures to normalize plasma lipoproteins include diet, exercise and drugs if needed. A working group of the International Society and Federation of Cardiology recommends the following:
-
1.
Reduction of saturated fat intake of no more than 8–10% of calories total fat no more than 25–30% of energy intake.
-
2.
Cholesterol intake of no more than 200-250 mg/day for adults.
-
3.
Ratio of polyunsaturated fatty acids to saturated fatty acids of 0.75–1.0.
-
4.
Dietary fibre intake of up to 30 g/day, derived chiefly from legumes, other vegetables and fruits.
-
5.
Gradual reduction of elevated body weight by restriction of energy intake (with attention to the qualitative recommendations above) and by physical exercise.
Although advice as above has been formulated over and over again, it is only realized in a minority of patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Pyörälä EdK, Rapaport E, Konig K, Schettler G, Diehm C: Secondary prevention of coronary heart Disease. Workshop of the International Society and Federation of Cardiology, Titisee, 21–24 October 1983. Georg Thieme Verlag, Stuttgart/New York, 1983.
Report of a WHO Expert Committee: Prevention of coronary heart disease, Technical Report Series 678, 1982, World Health Organization, Geneva, 1982.
Hulley StB, Lo B: Choice and use of blood lipid tests. Arch Intern Med 143: 667–673, 1983.
Klose G, Greten H: Risiko und Nutzen in der Behandlung von Hyperlipoproteinämien. In: Hyperlipoproteinämie. Hrsg. H. Kaffarnik/J Schneide perimed Fachbuch-Verlagsges. Er- langen, 1983, S. 160–167.
Hoffmeister h, Junge B, Schön D: Prävention von Herz-Kreislaufkrankheiten: Bewertung des Erfolgs von Interventionsstudien, Bundesgesundheitsblatt 27 Nr. 5, 1984.
Buchwald H, Fitch L, Moore RB: Overview of randomized clinical trials of lipid intervention for atherosclerotic disease. Controlled Clinical Trials 3: 271–283, 1982.
Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. J Am Med Assoc 321–360, 1975.
Rosenhammer G, Carlson LA: Effect of combined clofibrate — nicotinic acid treatment in ischemic heart disease. Atherosclerosis 37: 129–138, 1980.
Vessby B, Lithell H, Boberg J: Will serum lipid lowering treatment reduce the incidence of coronary heart disease? Artery 9: 372–381, 1981.
Blankenhorn DH: Angiographic evidence of atherosclerosis regression in man Atherosclerosis IV, 1979, Springer-Verlag, Berlin, Heidelberg, New York, 414–421.
Erikson U, Helmius G, Hemmingson A, Ruhn G, Olsson AG: Measurement of atherosclerosis by arteriography and microdensitometry: Model and clinical investigations Atherosclerosis VI, 1983, Springer-Verlag Berlin, Heidelberg, New York, 197–201.
Duffield RGM, Lewis B, Miller NE, Jamieson CW, Brunt JNH, Colchester ACF: Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. Lancet 11: 639–641, 1983.
Arntzenius AC, Barth JD, Bruschke AVG, Buis B, van Gent CM, Houtsmuller UMT, Kempen-Voogd N, Dr Kromhour, Reiber JHC, Strikwerda S, van der Velde EA, van Wezel LA: Preliminary report on coronary lesion and serum lipids before and after 2 years dietary intervention in 22 patients. Atherosclerosis VI, Ed. Schettler et al., Springer-Verlag Berlin/Heidelberg/New York, 1983, S. 187–193.
Nash DT Gensini G, Esente P: Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arterography. International Journal of Cardiology 2: 43–55, 1982.
Nikkilä EA, Viikinkoski P, Valle M, Frick MH: Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Brit Med J 289: 220–223, 1984.
Brensicke JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein StE: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II. Circulation 69: 313–324, 1984.
Schuler G, Wirth A, Schlierf G, Dinsenbacher A, Hofmann M, Rohrig N, Hartmann S, Kübler W: Dietary fat restriction and physical training in patients with coronary artery disease: ‘ideal’ plasma lipids without drugs (abstr.). Circulation Supp II: II–127, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
Schlierf, G. (1985). Lipid Lowering Regimens in Secondary Prevention of Coronary Heart Disease. In: Mathes, P. (eds) Secondary Prevention in Coronary Artery Disease and Myocardial Infarction. Developments in Cardiovascular Medicine, vol 48. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-5024-5_4
Download citation
DOI: https://doi.org/10.1007/978-94-009-5024-5_4
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8725-4
Online ISBN: 978-94-009-5024-5
eBook Packages: Springer Book Archive